Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisafotoclax + Decitabine + Homoharringtonine in AML Previously Treated With Venetoclax + Azacitidine
NCT07505160Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisaftoclax in acute myeloid leukemia (AML), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
lisaftoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07505160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07505160.